Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Growth Opportunities | Learn about Tandem's potential expansion into the Type 2 diabetes market, which could significantly increase its addressable market and drive long-term growth |
Competitive Pressures | Delve into Tandem's struggle to maintain market share amid fierce competition, with flat year-over-year new patient starts raising concerns |
Financial Outlook | Analysts project near-term challenges with negative EPS, but see potential for upward revisions. Price targets range from $58 to $65, signaling optimism |
Mobi's Market Impact | Explore how Tandem's Mobi insulin pump system is driving growth and outperforming expectations, positioning the company for potential market expansion |
Metrics to compare | TNDM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTNDMPeersSector | |
---|---|---|---|---|
P/E Ratio | −16.1x | −5.3x | −0.7x | |
PEG Ratio | −0.41 | 0.10 | 0.00 | |
Price / Book | 8.6x | 2.1x | 2.6x | |
Price / LTM Sales | 2.4x | 1.5x | 3.2x | |
Upside (Analyst Target) | 76.9% | 30.5% | 45.2% | |
Fair Value Upside | Unlock | −0.9% | 7.0% | Unlock |